This trial aimed to determine if first-line pembrolizumab was effective in treating patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC) who had high PD-L1 expression, in a real-world setting. Here, CD274 is linked to non-small cell lung carcinoma.